GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022

GEMINA LABORATORIES LTD. 

News Release 

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS 

December 19th 2022, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is pleased to announce that it has entered into a collaborative research  partnership focused on the development of wearable biosensors with Dr. Amanda Clifford at the  University of British Columbia.  

Dr. Clifford is a researcher and Assistant Professor at the UBC Department of Materials Engineering. She  holds a Bachelor of Engineering degree and Ph.D. from the Department of Materials Science and  Engineering at McMaster University. Dr. Clifford’s expertise and current research focuses on the  development of advanced materials for wearable healthcare monitoring and functional biointerfaces.  

This collaboration will explore combining Gemina’s promising biorecognition technology with Dr. Clifford’s novel functional materials to enable portable, wearable, non-invasive, and continuous  physiological monitoring. The goal of this initial research project is to conduct an initial proof of concept study, to validate that the two technologies can be successfully integrated. It is a programme of work that  lays the foundations for new types of diagnostic devices, including miniaturized, flexible, electronic devices that can be worn in the mouth for continuous saliva-based testing and reporting. 

“Gemina’s proprietary chemistry has consistently proven to be a highly effective and dynamic platform  that allows for the development of best in class diagnostics for both medical and personal wellness point  of care applications,” stated Gemina CTO Robert Greene. “Our vision for highly functionalized, next  generation biosensing is shared by Dr. Clifford. Her scientific acumen and current research program are a  perfect match with our chemistry, and I am extremely excited to see what we can accomplish together  over the next year.” 

Brian Firth, Gemina CEO commented, “The Gemina team is really pleased to be working with such an  exciting scientist at the outset of her career. Dr. Clifford is doing inspiring work creating next generation  architectures of sensing applications for human health and wellbeing. This collaboration is a clear  indication of the powerful potential of transformative chemistry, coupled with exciting new biosensing  devices.”  

Dr. Clifford added, “As a research scientist, my goal is to be able to translate new scientific breakthroughs  into real world applications that help solve real problems. One of the great strengths of Gemina’s  chemistry is that it can quickly and flexibly generate new prototype applications, which is a natural fit with  my highly translational research program. I am really looking forward to seeing the first results of this 

work early in 2023.” 

On Behalf of the Board of Directors 

John Davies 

CEO 

Gemina Laboratories Ltd.

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and  easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19,  influenza and other viruses. Additional information on the Company can be found at  www.geminalabs.com. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or  engagement. Information and statements which are not purely historical fact are forward-looking  statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

Brian Firth, CEO 

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

GEMINA LABS ANNOUNCES STRATEGIC STAKE IN BRITISH RAPID TEST OPTIMIZER RAPIVD LIMITED

December 7, 2022
Read More

GEMINA LABS ENTERS INTO LICENSE AND MANUFACTURING AGREEMENTS

October 6, 2022
Read More

GEMINA LABS PRESENTS AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

September 12, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.